MDACC Study No:2011-0844 ( NCT No: NCT01596127)
Title:Safety and Efficacy of Intrathecal Rituximab in Patients with Lymphoid Malignancies Involving the Central Nervous System
Principal Investigator:Elias Jabbour
Treatment Agent:Rituximab
Study Status:Open
Study Description:The goal of this clinical research study is to learn about the safety and
effectiveness of rituximab given by spinal tap in patients with lymphoid
malignancies involving the central nervous system.

A spinal tap (also called a lumbar puncture) is when fluid surrounding the
spinal cord is collected by inserting a needle into the lower back. The
affected area is numbed with local anesthetic during the procedure. It will
also be used to give chemotherapy in this study.

Rituximab is designed to bind to a protein, called CD20, that is on the surface
of the leukemia cells. This may cause the leukemia cells to die.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:Rituximab
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:N/A
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Elias Jabbour
For Clinical Trial Enrollment:713-792-4764
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults